-
1.发明申请PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME 审中-公开吡啶酰胺和嘧啶-4-羧酰胺化合物，其制备方法和包含其的药物组合物
公开(公告)号：WO2011139107A2
公开(公告)日：2011-11-10
申请号：PCT/KR2011/003362
申请日：2011-05-04
申请人： SK Chemicals Co.,Ltd. , RYU, Je Ho , KIM, Shin Ae , RYU, Keun Ho , KIM, Jae Sun , KIM, Nam Ho , HAN, Hye Young , KIM, Yong Hyuk , YOUN, Won-No , LEE, Yoon-Jung , SON, Hyun Joo , LEE, Bong-yong , PARK, Sung Hoon , LEE, Ju Young , LEE, Hyun Jung , JUNG, Hoe Chul , SHIN, Young Ah , LEE, Jung A , LEE, Bo Ram , SA, Joon Ho
发明人： RYU, Je Ho , KIM, Shin Ae , RYU, Keun Ho , KIM, Jae Sun , KIM, Nam Ho , HAN, Hye Young , KIM, Yong Hyuk , YOUN, Won-No , LEE, Yoon-Jung , SON, Hyun Joo , LEE, Bong-yong , PARK, Sung Hoon , LEE, Ju Young , LEE, Hyun Jung , JUNG, Hoe Chul , SHIN, Young Ah , LEE, Jung A , LEE, Bo Ram , SA, Joon Ho
IPC分类号： C07D401/04 , C07D401/14 , C07D413/14 , A61K31/444 , A61K31/496 , A61P3/10 , A61P3/06
CPC分类号： C07D401/04 , C07D213/81 , C07D239/557 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/12 , C07D405/14
摘要： Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11β-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11β-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human- derived 11β-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LAD A), insulin tolerance syndromes, obesity, impaired glucose tolerane (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.
摘要翻译： 提供了吡啶酰胺和嘧啶-4-甲酰胺化合物，其制备方法，含有该组合物的药物组合物，以及使用该化合物作为预防，调节和治疗与糖皮质激素调节有关的疾病的药物的用途 化合物对11β-HSD1酶的选择性抑制活性。 本发明的吡啶酰胺和嘧啶-4-甲酰胺化合物是人源性11β-HSD1酶的选择性抑制剂，可用于预防，调节和治疗与糖皮质激素调节有关的疾病的药剂，其中人源性11β- 涉及HSD1酶，例如代谢综合征，例如1型和2型糖尿病，糖尿病后期并发症，潜伏性自身免疫性糖尿病成人（LAD A），胰岛素耐受综合征，肥胖症，葡萄糖耐量降低（IGT），空腹血糖受损 IFG），葡萄糖耐量受损，血脂异常，动脉粥样硬化，高血压等。
-
2.发明申请LYOPHILIZED PHARMACEUTICAL COMPOSITION WITH IMPROVED STABILITY CONTAINING TAXANE DERIVATIVES, AND METHOD OF MANUFACTURING THE SAME 审中-公开含有TAXANE衍生物的改进的稳定性的LYOPHILIZED药物组合物及其制备方法
公开(公告)号：WO2009066955A2
公开(公告)日：2009-05-28
申请号：PCT/KR2008006875
申请日：2008-11-21
申请人： SK CHEMICALS CO LTD , HWANG YONG YOUN , JANG WOO JAE , OH JOON-GYO , KIM NAM HO , KIM JAE-SUN , UM KEY AN
发明人： HWANG YONG YOUN , JANG WOO JAE , OH JOON-GYO , KIM NAM HO , KIM JAE-SUN , UM KEY AN
IPC分类号： A61K9/19
摘要： The present invention relates to a lyophilized pharmaceutical composition for injection having superior storage stability comprising a taxoid, and a method thereof. More specifically, the present invention relates to a lyophilized pharmaceutical composition for injection having improved solubility and stability of dilution compared to the conventional preparations by dissolving a water-insoluble taxoid in distilled water added with a hydrophilic polymer such as hydroxypropylmethyl cellulose(HPMC), polyethylene glycol (PEG) or polyvinylpyrrolidone(PVP)cyclodextrin (CD), and lyophilizing the mixture and a method thereof.
摘要翻译： 本发明涉及具有优异的储存稳定性的冻干药物组合物，其包含紫杉烷类及其方法。 更具体地，本发明涉及一种用于注射的冻干药物组合物，其与常规制剂相比，通过将水不溶性紫杉烷溶解在加入亲水性聚合物如羟丙基甲基纤维素（HPMC），聚乙烯的蒸馏水中而具有改善的溶解度和稳定性 乙二醇（PEG）或聚乙烯吡咯烷酮（PVP）环糊精（CD），并冻干该混合物及其方法。
-
3.发明申请
公开(公告)号：WO2007073095A1
公开(公告)日：2007-06-28
申请号：PCT/KR2006/005602
申请日：2006-12-20
发明人： LEE, Jin Young , KIM, Nam Ho , KIM, Jae-Sun , LEE, Nam Kyu
IPC分类号： C07D495/04 , C07D513/08 , C07D498/02 , A61P7/02 , A61P9/10
CPC分类号： C07D495/04
摘要： The present invention relates to a process for preparing S-(+)-clopidogrel using a solid-phase reaction, and more particularly, to a process for preparing S-(+)- clopidogrel represented by the following formula 1 with high optical and chemical purity by carrying out a series of reactions and purifications more simply by a solid- phase synthetic approach using a polymer support.
摘要翻译： 本发明涉及一种使用固相反应制备S - （+） - 氯吡格雷的方法，更具体地说，涉及一种用高光学和化学药物制备由下式1表示的S - （+） - 氯吡格雷的方法 通过使用聚合物载体的固相合成方法更简单地进行一系列反应和纯化，从而获得纯度。
-
公开(公告)号：WO2005077942A1
公开(公告)日：2005-08-25
申请号：PCT/KR2005/000365
申请日：2005-02-07
申请人： SK CHEMICALS, CO., LTD. , LEE, Nam Kyu , LEE, Ju Young , KIM, Jae-Sun , JUNG, Jae Yoon , UM, Key An , OH, Yong Ho , SHIN, Ho Chul , JANG, Woo Jae , IM, Guang-Jin , KIM, Tae Kon
发明人： LEE, Nam Kyu , LEE, Ju Young , KIM, Jae-Sun , JUNG, Jae Yoon , UM, Key An , OH, Yong Ho , SHIN, Ho Chul , JANG, Woo Jae , IM, Guang-Jin , KIM, Tae Kon
IPC分类号： C07D405/04
CPC分类号： C07D405/04
摘要： The present invention relates to a novel method of synthesizing substituted benzopyran compounds, their novel intermediates and a method of their preparation thereof.
摘要翻译： 本发明涉及一种合成取代苯并吡喃化合物的新方法及其新型中间体及其制备方法。
-
5.发明申请2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS 审中-公开2-PYRIDYL取代的咪唑烷作为ALK5和/或ALK4抑制剂
公开(公告)号：WO2013009140A3
公开(公告)日：2013-04-11
申请号：PCT/KR2012005617
申请日：2012-07-13
申请人： SK CHEMICALS CO LTD , LEE JU YOUNG , RYU KEUN-HO , KIM JAE-SUN , KIM YONG-HYUK , SHIN DONG CHUL , LEE BONG-YONG , KANG SANG-HWAN , LEE HYUN JUNG , JUNG HOECHUL , SHIN YOUNG AH , PARK EUISUN , AHN JAESEUNG
发明人： LEE JU YOUNG , RYU KEUN-HO , KIM JAE-SUN , KIM YONG-HYUK , SHIN DONG CHUL , LEE BONG-YONG , KANG SANG-HWAN , LEE HYUN JUNG , JUNG HOECHUL , SHIN YOUNG AH , PARK EUISUN , AHN JAESEUNG
IPC分类号： C07D487/04
CPC分类号： C07D487/04 , C07D519/00
摘要： The present invention provides a novel 2-pyridyl substituted imidazole derivative, or a pharmaceutically acceptable salt or solvate thereof, which selectively inhibits the transforming growth factor-beta (TGF-beta) type I receptor (ALK5) and/or the activin type I receptor (ALK4); a pharmaceutical composition comprising same as an active ingredient; and a use of the 2-pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal.
摘要翻译： 本发明提供了选择性抑制转化生长因子-β（TGF-β）I型受体（ALK5）和/或激活素I型受体的新型2-吡啶基取代的咪唑衍生物或其药学上可接受的盐或溶剂合物 （ALK4）; 包含其作为活性成分的药物组合物; 以及2-吡啶基取代的咪唑衍生物在制备用于预防或治疗由哺乳动物中ALK5和/或ALK4受体介导的疾病的药物中的用途。
-
6.发明申请COMPOSITION FOR TRANSDERMAL ADMINISTRATION, CONTAINING RIVASTIGMINE OR SALT THEREOF 审中-公开含有盐酸盐或盐的超导管理组合物
公开(公告)号：WO2012157921A3
公开(公告)日：2013-03-21
申请号：PCT/KR2012003756
申请日：2012-05-14
申请人： SK CHEMICALS CO LTD , HWANG YONG-YOUN , CHOI WON-JAE , KIM JAE-SUN , YOUN WON-NO , PARK YEO-JIN , OJ JOON-GYO , IM JONGSEOB
发明人： HWANG YONG-YOUN , CHOI WON-JAE , KIM JAE-SUN , YOUN WON-NO , PARK YEO-JIN , OJ JOON-GYO , IM JONGSEOB
IPC分类号： A61K31/325 , A61K9/70 , A61K31/195 , A61P17/00
CPC分类号： A61K31/27 , A61K9/0014 , A61K31/192 , A61K2300/00
摘要： The present invention relates to a composition for transdermal administration with improved storage stability, containing rivastigmine or a salt thereof. The composition for transdermal administration of the present invention uses gentisic acid as a stabilizer of rivastigmine, wherein gentisic acid has greater rivastigmine stability than tocopherol, a formulation used on the market, is easy to handle and is commercially cheap. According to the present invention, the composition has improved stability, and thus can be stored for a long time as a drug for transdermal administration.
摘要翻译： 本发明涉及具有改善的储存稳定性的透皮给药组合物，其含有利伐斯的明或其盐。 用于本发明透皮给药的组合物使用龙胆酸作为利伐斯的明的稳定剂，其中龙胆酸具有比生育酚更好的利伐斯的明稳定性，市售上使用的制剂易于处理并且商业上便宜。 根据本发明，组合物具有改善的稳定性，因此可以长时间作为透皮给药用药物储存。
-
7.发明申请
公开(公告)号：WO2013036081A2
公开(公告)日：2013-03-14
申请号：PCT/KR2012/007241
申请日：2012-09-07
申请人： SK CHEMICALS CO., LTD. , Lee, Soo-Min , Lee, Sooheun , Ryu, Keun-Ho , LEE, Bong-Yong , Kim, Jae-Sun , OH, Jung-hoon , JEON, Ye-ji
发明人： Lee, Soo-Min , Lee, Sooheun , Ryu, Keun-Ho , LEE, Bong-Yong , Kim, Jae-Sun , OH, Jung-hoon , JEON, Ye-ji
IPC分类号： A61K31/519
CPC分类号： A61K8/4953 , A61K31/00 , A61K31/519 , A61Q19/00 , A61Q19/08
摘要： Disclosed is a composition effective in reducing skin wrinkles. The composition comprisesa phosphodiesterase 5 (PDE5) inhibitor, preferably the compound of chemical formula 1, more preferably, mirodenafil as an active ingredient. Further disclosed is a method for reducing skin wrinkles using the composition.
摘要翻译： 公开了一种有效减少皮肤皱纹的组合物。 该组合物包含磷酸二酯酶5（PDE5）抑制剂，优选化学式1化合物，更优选米罗达非敏作为活性成分。 进一步公开了使用该组合物减少皮肤皱纹的方法。
-
8.发明申请2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS 审中-公开2-PYRIDYL取代的咪唑烷作为ALK5和/或ALK4抑制剂
公开(公告)号：WO2013009140A2
公开(公告)日：2013-01-17
申请号：PCT/KR2012/005617
申请日：2012-07-13
申请人： SK CHEMICALS CO., LTD. , LEE, Ju Young , RYU, Keun-Ho , KIM, Jae-Sun , KIM, Yong-Hyuk , SHIN, Dong Chul , LEE, Bong-yong , KANG, Sang-hwan , LEE, Hyun Jung , JUNG, Hoechul , SHIN, Young Ah , PARK, Euisun , AHN, Jaeseung
发明人： LEE, Ju Young , RYU, Keun-Ho , KIM, Jae-Sun , KIM, Yong-Hyuk , SHIN, Dong Chul , LEE, Bong-yong , KANG, Sang-hwan , LEE, Hyun Jung , JUNG, Hoechul , SHIN, Young Ah , PARK, Euisun , AHN, Jaeseung
IPC分类号： C07D487/04
CPC分类号： C07D487/04 , C07D519/00
摘要： The present invention provides a novel 2-pyridyl substituted imidazole derivative, or a pharmaceutically acceptable salt or solvate thereof, which selectively inhibits the transforming growth factor-β (TGF-β) type I receptor (ALK5) and/or the activin type I receptor (ALK4); a pharmaceutical composition comprising same as an active ingredient; and a use of the 2-pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal.
摘要翻译： 本发明提供了选择性抑制转化生长因子-β（TGF-β）I型受体（ALK5）和/或激活素I型受体的新型2-吡啶基取代的咪唑衍生物或其药学上可接受的盐或溶剂合物 （ALK4）; 包含其作为活性成分的药物组合物; 以及2-吡啶基取代的咪唑衍生物在制备用于预防或治疗由哺乳动物中ALK5和/或ALK4受体介导的疾病的药物中的用途。
-
9.发明申请COMPOSITION FOR PERCUTANEOUS ADMINISTRATION OF TOLTERODINE WITH REDUCED SKIN IRRITATION 审中-公开用于皮肤刺激减轻的多巴酚丁胺治疗组合物
公开(公告)号：WO2011102655A3
公开(公告)日：2012-01-19
申请号：PCT/KR2011001061
申请日：2011-02-17
申请人： SK CHEMICALS CO LTD , HWANG YONG YOUN , CHOI WON-JAE , KIM JAE-SUN , PARK YEO-JIN , OH JOON-GYO , RHEE HAE-IN , IM JONG-SEOB , LEE BONG-YONG
发明人： HWANG YONG YOUN , CHOI WON-JAE , KIM JAE-SUN , PARK YEO-JIN , OH JOON-GYO , RHEE HAE-IN , IM JONG-SEOB , LEE BONG-YONG
IPC分类号： A61K47/44 , A61K31/137 , A61P13/10
CPC分类号： A61K31/137 , A61K9/7061 , A61K47/44
摘要： The present invention relates to a composition for percutaneous administration, in which an essential oil serving as an abirritant is mixed to minimize skin irritation caused by the composition for percutaneous administration, containing tolterodine. The composition for percutaneous administration according to the present invention reduces skin irritation caused by tolterodine, thereby making percutaneous preparations containing tolterodine commercially available.
摘要翻译： 本发明涉及一种用于经皮给药的组合物，其中将用作刺激剂的精油混合以使包含托特罗定的经皮给药组合物引起的皮肤刺激最小化。 根据本发明的用于经皮给药的组合物减少了托特罗定引起的皮肤刺激，由此制备了含有托特罗定的经皮制剂。
-
10.发明申请COMPOSITION FOR PERCUTANEOUS ADMINISTRATION OF TOLTERODINE WITH IMPROVED SKIN PERMEATION 审中-公开用于皮肤渗透性改善的多巴酚丁胺治疗组合物
公开(公告)号：WO2011102657A3
公开(公告)日：2012-01-12
申请号：PCT/KR2011001064
申请日：2011-02-17
申请人： SK CHEMICALS CO LTD , HWANG YONG YOUN , CHOI WON-JAE , KIM JAE-SUN , PARK YEO-JIN , OH JOON-GYO , IM JONG-SEOB , RHEE HAE-IN , LEE BONG-YONG
发明人： HWANG YONG YOUN , CHOI WON-JAE , KIM JAE-SUN , PARK YEO-JIN , OH JOON-GYO , IM JONG-SEOB , RHEE HAE-IN , LEE BONG-YONG
IPC分类号： A61K9/70 , A61K31/137 , A61P13/10
CPC分类号： A61K9/7061 , A61K31/137 , A61K31/167 , A61K2300/00
摘要： The present invention relates to a composition for percutaneous administration, containing tolterodine, wherein the composition comprises lidocaine or pharmaceutically acceptable salts thereof so as to improve skin permeation. The composition for percutaneous administration according to the present invention improves skin permeation of tolterodine, thereby making percutaneous preparations of tolterodine commercially available.
摘要翻译： 本发明涉及含有托特罗定的经皮给药组合物，其中组合物包含利多卡因或其药学上可接受的盐，以改善皮肤渗透。 根据本发明的用于经皮给药的组合物改善了托特罗定的皮肤渗透，从而使得托特罗定的经皮制剂可商购。
-
-
-
-
-
-
-
-
-
搜索结果
41 条记录 (耗时 0.015 秒)
